Trial Profile

A Single Arm Phase-IV Study to Determine Reactogenicity and Immunogenicity of Delayed COVID-19 Vaccine Schedule in Children

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 06 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tozinameran (Primary)
Indications COVID 2019 infections
Focus Pharmacodynamics

Most Recent Events

06 May 2022 The primary endpoint was changed from To evaluate immunogenicity at 2 months after one dose BNT162b2 vaccination in children 5 to 11 years old to Percentage neutralizing antibody levels at 2m, WHO International units/ml neutralizing antibody levels at 2m, and Geometric mean titres (GMT) neutralizing antibody levels at 2m, according to ClinicalTrials.gov record.
19 Apr 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com